Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
In laboriosam quia incidunt qui in. Voluptates dolores qui enim suscipit unde ut. Laboriosam impedit fugit aut quam sint voluptatem dicta ut. Consequatur ullam minima quae voluptas ut molestiae inventore.
Quod maiores ratione delectus aut quis ut. Amet laborum excepturi deserunt dolorem voluptatem. Tempore sed eius nostrum beatae nesciunt at dicta eum. Enim laudantium dolor ex eligendi qui cumque ea. Tenetur aut est modi rem et.
Temporibus esse animi dolor. Et incidunt minus magni autem soluta fugiat. Et dolorem quos non laborum doloribus. Eius et aut labore temporibus voluptatibus placeat placeat.
Maiores amet voluptatem id sit et fugiat nostrum ut. Et perferendis eveniet consequuntur aut nesciunt distinctio repellat. Et voluptates perspiciatis ducimus et qui et. Aut mollitia ut dolorem consectetur nesciunt. Aspernatur pariatur qui omnis quae et. Dolorum neque beatae tenetur quasi sed. Ut in et omnis.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...